As of 2025-07-09, the EV/EBITDA ratio of Finch Therapeutics Group Inc (FNCH) is -0.34. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FNCH's latest enterprise value is 5.16 mil USD. FNCH's TTM EBITDA according to its financial statements is -15.40 mil USD. Dividing these 2 quantities gives us the above FNCH EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.2x - 12.8x | 10.5x |
| Forward P/E multiples | 11.9x - 20.6x | 16.2x |
| Fair Price | (14.20) - (15.37) | (16.12) |
| Upside | -888.7% - -954.0% | -995.8% |
| Date | EV/EBITDA |
| 2025-07-07 | -8.90 |
| 2025-07-03 | -8.96 |
| 2025-06-26 | -9.06 |
| 2025-06-24 | -8.90 |
| 2025-06-23 | -8.91 |
| 2025-06-20 | -9.25 |
| 2025-06-18 | -9.23 |
| 2025-06-17 | -9.36 |
| 2025-06-16 | -9.36 |
| 2025-06-13 | -9.48 |
| 2025-06-12 | -8.81 |
| 2025-06-11 | -9.44 |
| 2025-06-09 | -9.20 |
| 2025-06-06 | -9.34 |
| 2025-06-04 | -9.32 |
| 2025-06-02 | -9.36 |
| 2025-05-30 | -9.28 |
| 2025-05-29 | -9.38 |
| 2025-05-27 | -9.44 |
| 2025-05-23 | -8.90 |
| 2025-05-22 | -8.90 |
| 2025-05-21 | -9.36 |
| 2025-05-20 | -9.36 |
| 2025-05-19 | -9.27 |
| 2025-05-16 | -9.10 |
| 2025-05-15 | -9.06 |
| 2025-05-14 | -8.94 |
| 2025-05-13 | -9.03 |
| 2025-05-12 | -8.87 |
| 2025-05-08 | -9.28 |
| 2025-05-06 | -8.71 |
| 2025-05-05 | -8.56 |
| 2025-05-02 | -8.70 |
| 2025-05-01 | -8.71 |
| 2025-04-30 | -8.52 |
| 2025-04-29 | -8.37 |
| 2025-04-28 | -8.37 |
| 2025-04-25 | -8.60 |
| 2025-04-24 | -8.40 |
| 2025-04-23 | -8.63 |
| 2025-04-22 | -8.71 |
| 2025-04-21 | -8.86 |
| 2025-04-17 | -8.90 |
| 2025-04-16 | -8.90 |
| 2025-04-15 | -9.13 |
| 2025-04-14 | -9.21 |
| 2025-04-11 | -8.44 |